Physician profile
Zonghao Pan
NPI 1912670514
$945.49
in general payments reported to CMS, 2019-2025
15 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $136 · 2022: $234 · 2023: $220 · 2024: $251 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $245.36 | 2021-2024 | Airsupra |
| Abbvie INC. | $148.67 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Genzyme Corporation | $124.51 | 2023 | |
| Astellas Pharma US INC | $52.00 | 2025 | Cresemba |
| Novo Nordisk INC | $36.06 | 2021-2024 | |
| Stryker Corporation | $35.43 | 2025 | Clottriever Bold Catheter |
| Exact Sciences Corporation | $35.41 | 2023 | Cologuard Collection Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.50 | 2022 | |
| Emd Serono, INC. | $24.13 | 2024 | |
| Aimmune Therapeutics, INC. | $21.07 | 2024 | |
| Glaxosmithkline, LLC. | $18.80 | 2023 | Arexvy, Shingrix |
| Actelion Pharmaceuticals US, INC. | $18.19 | 2023 | Uptravi, Opsumit |
| Irhythm Technologies, INC. | $17.18 | 2022 | |
| Neurelis, INC. | $15.18 | 2024 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zonghao Pan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.